Related Experiment Video
Updated: Jul 2, 2025
05:33
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
9.7K
mRNA PROTACs: engineering PROTACs for high-efficiency targeted protein degradation
Xiaoqi Xue1, Chen Zhang1, Xiaolin Li1
1State Key Laboratory of Chemical Oncogenomics Institute of Biopharmaceutical and Health Engineering Shenzhen International Graduate School, Tsinghua University Shenzhen China.
Medcomm
|February 20, 2024
Summary
We developed mRNA proteolysis-targeting chimeras (mPROTACs) to degrade target proteins. These mPROTACs show enhanced efficacy in degrading cancer proteins and inhibiting cell proliferation compared to peptide PROTACs, leading to significant tumor regression in vivo.
Area of Science:
- Biochemistry
- Molecular Biology
- Therapeutic Development
Background:
- Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules for targeted protein degradation.
- Their therapeutic potential is significant but largely untapped.
- mRNA therapies offer scalability and low cost, presenting an opportunity for novel PROTAC development.
Purpose of the Study:
- To engineer mRNA-based PROTACs (mPROTACs) for efficient targeted protein degradation.
- To evaluate the efficacy of mPROTACs against cancer-related proteins.
- To compare mPROTACs with traditional peptide PROTACs (pPROTACs).
Main Methods:
- Designed mPROTACs by combining mRNA encoding a von Hippel-Lindau (VHL) recruiting peptide and a protein of interest (POI)-binding peptide.
- Conducted proof-of-concept experiments targeting estrogen receptor alpha and B-cell lymphoma-extra large protein.
- Assessed POI degradation, cell proliferation inhibition, and in vivo tumor regression in a mouse xenograft model.
Main Results:
- mPROTACs successfully degraded target proteins in various cell lines.
- mPROTACs demonstrated more effective inhibition of cancer cell proliferation than pPROTACs.
- In vivo experiments showed significant tumor regression in the 4T1 mouse xenograft model using mPROTACs.
Conclusions:
- mRNA PROTACs represent a novel and promising strategy for targeted protein degradation therapy.
- mPROTACs offer enhanced therapeutic potential compared to traditional pPROTACs.
- This approach holds significant promise for developing new cancer treatments.
Related Concept Videos
02:18The Proteasome
8.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.6K
01:24Tagging and Fusion Proteins
6.6K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
6.6K
02:58Regulated Protein Degradation
7.3K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.3K
02:51mRNA Stability and Gene Expression
5.6K
The structure and stability of mRNA molecules regulates gene expression, as mRNAs are a key step in the pathway from gene to protein. In eukaryotes, the half-life of mRNA varies from a few minutes up to several days. mRNA stability is essential in growth and development. The absence of the proteins regulating its stability, such as tristetraprolin in mice, can cause systemic issues, including bone marrow overgrowth, inflammation, and autoimmunity.
Cis-acting Elements involved in mRNA stability
Cis-acting Elements involved in mRNA stability
5.6K
01:32Export of Misfolded Proteins out of the ER
3.6K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.6K
01:34Directing Proteins to the Rough Endoplasmic Reticulum
7.3K
The organelle-specific signaling sequences direct proteins synthesized in the cytosol to their final destination like ER, mitochondria, peroxisomes, etc. Some of the proteins directed to ER are then trafficked via vesicles to other organelles within the cell or the extracellular environment through the Golgi complex. For example, the rough ER synthesizes soluble proteins for transportation to the lysosomes or secretion out of the cell. It can also synthesize transmembrane proteins that can...
7.3K